StemCell Therapy

The World Potato Congress (WPC) is pleased to be offering thefirst webinar in its 2020series featuring Dr. David Douches on January 24, 2020 at 09:00 AM Eastern Standard Time (USA and Canada).

Abstract:The Feed the Future Biotechnology Potato Partnership (BPP) is a five-year, multi-institution cooperative agreement between MSU, USAID, Simplot Company and other global institutions to develop and bring to market improved potato products to low-income farmers in South East Asian countries.

BPP offers biotech potato products with broad-spectrum resistance to late blight (Phytophthorainfestans), the most devastating potato disease in the world, and highly endemic throughout Bangladesh and Indonesia. BPP provides strategic human and institutional capacity building and support (research, development and outreach) to in-country partners in Bangladesh (BARI) and Indonesia (ICABIOGRAD) to support access to, technology transfer, and sustainable use of biotech potato technologies.

The project also monitors and evaluates environmental impact, gender balance contribution and socio-economic impact of these biotechnologies. BPP and partner institutions will steward biotech potato products for distribution to low-income farmers and eventual commercialization. All of these activities support and align with USAIDs goal of increasing food security and resilience.

Dr. David S. Douches, with over 36 years of experience inpotato breeding and genetics, has an active potato breeding program directedtoward the development of improved cultivars in Michigan for 30 years.

Thefocus of the program is to develop new cultivars for Michigans potato industryby integrating new genetic engineering techniques with conventional breedingefforts.Key traits targeted forimprovement include Colorado potato beetle resistance, disease resistance to scab, lateblight and PVY, as well as chip processing from long-term storage.

Dr. Douches is the principle scientist of the Michigan State Universitypotato breeding and genetics program and Director of the USAID-fundedFeed the Future Biotechnology Potato Project for Indonesia and Bangladesh.

The host for the WPC webinar series will be WPC Director, Dr. Nora Olsen (norao@uidaho.edu).

Webinar RegistrationInterested participants will be able to interact with the presenterof the webinar. When: January 24, 2020 at 09:00 AM Eastern Standard Time (USA and Canada)

Register in advance for this webinar:https://zoom.us/webinar/register/WN_Svl0vOiUQyKZqtjfYCzqpgFollowing your registration, you will receive a confirmation email containing information about how to join the webinar.

All webinars are recorded and can be viewed via the World Potato Congresswebsite at http://www.potatocongress.org.

In case you missed any of WPCs 2019webinars listed below, they can be viewed on our website at http://www.potatocongress.org :

1.World Potato Congress Inc. Premier Global Networking OrganizationPresenter: WPC President, Romain Cools, Belgium

2.Geographic Constraints in Potato Breeding: Role of Day Length, Temperature and Light Intensity in Selecting for AdaptationPresenter: Dr. Peter VanderZaag, Sunrise Potato Storage Ltd., Canada

3.Best Management Practices for Seed Potato Handling from Storage to PlantingPresenter: Dr. Gary Secor, Professor in the Department of Plant Pathology, North Dakota State University, USA

4.World Potato Output and TradePresenter: Cedric Porter, Editor, Brexit Food & Farming and co-editor of World Potato Markets, UK

5.Why You Should Plant Certified Seed PotatoesPresenter: Dr. Nina Zidack, Director of Seed Potato Certification, Montana State University, USA

6. Illustration of Regional Potato Promotion:Flanders (Belgium)Presenter:Kris Michiels, Marketing Adviser, VLAM, Belgium

WPC looks forward to interacting with you during this initiative. We welcome all your feedback via email:info@potatocongress.org.

Like Loading...

Categories: Across Regions, All latest News, Breeding, Events, News January 2020, North America, Pests and Diseases, Pressreleases, Production/Agronomy, Research, Studies/Reports, Varieties

Read the rest here:
Webinar: Feed the Future Biotechnology Potato Partnership: Durable late blight resistance to South East Asia - Potato News Today

Nasdaq recently announced the results of the annual re-ranking of the Nasdaq Biotechnology Index (NBI). The re-ranking was effective prior to market open on Monday, December 23, 2019. There are now 217 companies in the index, including 40 new additions. You can view the full list of securitieshere.

Along with this performance was a substantial increase in assets under management (AUM) for IBB the largest corresponding ETF that tracks the Nasdaq Biotechnology Index globally. In fact, the AUM as of December 31, 2019 was approximately $8B.

Since its inception, the NBI has shown impressive performance over the years. The market capitalization weighted index focuses specifically on the biopharmaceutical industry allowing Nasdaq-listed companies to gain exposure to passive investors.

Nasdaq continues to be the leader in biotechnology listings, including initial public offerings in the biotechnology and pharmaceutical arena such as Genmab, Bridge Bio and Gossamer Bio, Inc. In 2019, Nasdaq had a 100% BioPharma IPO win rate as we welcomed 55 BioPharma IPOs raising approximately $5.6 billion in IPO proceeds.

If you have any questions, including how to leverage inclusion in the index, please do not hesitate to contact me at Jordan.Saxe@nasdaq.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more:
40 Securities Added to Nasdaq Biotechnology Index - Nasdaq

Paris, France, January 9, 2020 Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of 18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi. This follows a seed funding round of 1.5M ($1.7M) in 2017, led by AFB.Founded by Pr Armand Bensussan, head of the Skin Research Centre, Saint Louis Hospital, Paris, and Pr Daniel Olive, head of the Immunity and Cancer team at Institut Paoli Calmette, Marseille, Alderaan Biotechnology focusses on developing technologies to deplete regulatory T (Treg) cells in cancer and to boost Natural Killer (NK) cell cytotoxic activity in cancer, both emerging as new immunotherapy modalities.This funding round will support the finalization of preclinical development to reach Phase I clinical stage, with the companys Treg depleting CD25-specific antibodies, by 2022. In parallel, the financing will also help validate thein vivotherapeutic potential of the NK asset related to the activating NK cell receptor CD160-TM (Alderaans second program).Both Medicxi and AFB, represented by Michle Ollier and Matthieu Coutet respectively, will co-lead the new investment as board directors.I am very pleased to welcome Medicxi to the company; its capital investment signals an exciting stage for Alderaan, said Arnaud Foussat, CEO of Alderaan Biotechnology. Modulating regulatory T-cells in cancer has a great therapeutic potential in oncology it could be a game changer. Our NK asset is earlier stage, but there is already a strong and encouraging interest from the pharmaceutical industry in the field.We have been working alongside Alderaan since day one and we are thrilled to be part of this next stage of development, said Matthieu Coutet, managing partner at Advent France Biotechnology. Alderaans area of focus is drawing attention from big names in the industry and the company has a solid scientific team to support its rationale.Alderaan perfectly fits with our aim, which is to invest in start-ups that have already reached scientific maturation and proof-of-concept, said Michle Ollier, partner at Medicxi. The companys technologies are very attractive to the pharmaceutical industry and could become key additional therapeutic tools for patients and health professionals.Advisors to AlderaanLegal: Mac DermottFinancial: DeloitteAdvisors to MedixciLegal: Jones DayAbout Advent France BiotechnologyAdvent France Biotechnology is an AMF regulated firm created in 2016. The team, managed by Alain Huriez and Matthieu Coutet, includes professionals with extensive scientific, medical and operational experience, as well as a long-standing track record of entrepreneurial and investment successes across Europe. AFB invests in a range of sectors within the life sciences, specifically in drug discovery and new medical technologies.www.adventFB.comAbout MedicxiMedicxi is a European venture capital firm with the mission to create and invest in companies along the full drug development continuum. Medicxi was established by the former Index Ventures life sciences team, which has been active for over 20 years, and invests in both early and late-stage assets with a product vision that can fulfil a clear unmet need.GSK, Johnson & Johnson Innovation JJDC, Inc.,Novartis and Verily (an Alphabet company) have invested in Medicxi funds.www.medicxi.comAbout Alderaan BiotechnologyAlderaan Biotechnology is a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer with technologies aiming at Treg depletion and NK cell modulation. Founded in 2017 and headquartered in Paris, Alderaan works with world-class teams in the field of immunomodulation and NK cell receptors. The company raised 1.5M ($1.7M) in 2017 from co-founder Advent France Biotechnology (AFB) and 18.5M ($20.7M) in 2019 from AFB and Medicxi.www.linkedin.com/company/alderaan-biotechnology/about/

The rest is here:
Alderaan Biotechnology raises 18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi - BioSpace

In silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.

French in silico clinical trial specialist Novadiscovery said it will use the 5m tranche of a 7m Series A funding round with Debiopharm Innovation Fund SA to scale its in silico clinical trial simulation platform Jink from a consulting to software as a service (SaaS) model, which is compliant with FDA priorities and requirements. Novadiscovery pioneers the use of in silicoclinical trials prior to human drug testing to predict drug efficacy and optimize clinical trail design. Several hundred disease and disease subtype-specific parameters are combined in the company's in silico models that mimic the physiology and co-morbidities of virtual patients.

Knowledge-based in silico modelling of clinical trials holds the potential to predict outcomes and optimise the design of clinical trials with the aim to reduce research & development (R&D) costs and time-to-market of novel drugs. Most recently, Novadiscovery accurately modelled the Phase I outcomes of the FXR agonist EYP001 in healthy and subjects infected with the hepatitis B virus (HBX) in a Phase I study. Furthermore, Jink was used to predict Phase II outcomes of a combination of EYP001 with standard therapy.

The Computational Model integrates 300+ biological variables and 600+ parameters. With seven mechanistic submodels (including the effect of FXR agonist on HBV replication, HBV excretion, bile acid physiology and EYP001, ETV, and pegylated interferon drug models), the model has been used to predict quantitative efficacy of treatments on disease-related endpoints (eg. plasma HBV DNA and HBsAg concentrations) in a virtual population. All the submodels are ultimately combined into a multi-scale Computational Model simulating the dynamics of biological entities at the molecular, cellular and organ levels.

We have seen the significant positive impact our in silico trials platform can have on reducing R&D costs and compressing time-to-market for new drugs and in drug repositioning, stressed Franois-Henri Boissel, CEO and Co-Founder of Nova. This funding allows us to accelerate the development of our platform in a SaaS model that will make it available to a growing number of clients and project, notably in the US. We intend to complete the 7m Series A in 2020.

Reducing R&D costs and time-to-market has become a key strategic objective for healthcare companies and payors. The in silico trial market is evaluated to grow to $2,88bn in annual revenue by 2022, when it will still represent only a small fraction of $165bn annual drug R&D spent.

Reducing number of real patients involved in clinical trials is also a main issue, for both the industry and the regulators. Because they are not so many considering the number of drugs to be evaluated, and their participation in a clinical trial must be as ethical as possible. Novas unique hybrid approach to running in silico clinical trials presents several benefits, one of which being that it can operate in data-poor environments, which is the biggest hurdle more conventional artificial intelligence (AI)-based approaches are facing.

View original post here:
Novadiscovery takes off with 5 Series A financing - European Biotechnology

Published: 16:50 Updated: 17:04 Monday 06 January 2020

A renowned scientist and former Tomorrows World presenter has been announced as one of the keynote speakers at the Industrial Biotechnology Innovation Centre (IBioIC) annual conference next month.

Vivienne Parry will address the event, which is now in its sixth year and expected to attract more than 450 delegates including IB business leaders, policy-makers, investors and innovators and technical experts from around the world. They will congregate in Glasgow on 5 and 6 February, and will see innovative companies exhibiting their smart solutions to a global audience.

Parry, a scientist by training, is the head of engagement at Genomics England and a UK Research and Innovation board member and has extensive writing and broadcasting experience that has inspired a generation of scientists.

She said industrial biotechnology (IB) start-ups need to get out and tell people what they are doing, quickly showing the solution to a problem scientists can sometimes struggle to communicate to policy-makers and the public the significance of what they are doing to save the planet.

READ MORE: Comment: Ever heard of industrial biotechnology? Our future may depend on itREAD MORE: Plans to boost Scotlands bio-revolution secure seed fundingKeep it simple and show the real value in your product and the positive impact it can make to everyday life and the environment. When I listen to someone presenting their concepts, I want them to excite me about the potential of their product in a way that is not hyped, but is really clear.

Mark Bustard, commercial director at IBioIC, said a change in mindset is needed if startups are to capitalise on their innovations. Companies like ScotBio, Cellucomp and Celtic Renewables are all fantastic examples of award-winning organisations who are driving science to generate and make products.

Link:
Former Tomorrows World presenter set to address biotechnology event - The Scotsman

Debut Biotechnology

SAN DIEGO (PRWEB) January 07, 2020

Debut Biotechnology, a UC-Irvine spinout that is advancing scalable cell-free biomanufacturing, today announced that it has closed a $2.6M seed round from leading venture capital firms and angel investors. The oversubscribed round was led by KdT Ventures, with participation from Better Ventures, FTW Ventures, and SpringTide Ventures.

We invested in Debut because the way we produce therapeutics and high value chemicals will dramatically change in the next 10 years as the pharma industry transitions from complex, multi-step batch manufacturing, to a far more cost-effective and efficient continuous manufacturing system, said Cain McClary, Founder and Managing Partner of KdT Ventures. Debut Bio will be at the forefront of this shift, which we believe represents one of the most promising opportunities in pharma.

Debut Bio helps the pharmaceutical and specialty chemical industries manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high value therapeutics and specialty chemicals.

At our core, we are rethinking industrial biomanufacturing and aiming to produce high value molecules in better ways. Natures enzymes have the ability to create complex natural products, so why reinvent the wheel with chemical synthesis? said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Enzyme pathways and evolved proteins hold the key.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional pharma manufacturing and avoids the use of environmentally harmful chemistry. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing.

Bacteria and yeast have been the workhorses of industrial biomanufacturing for years. Unfortunately, these biofactories have their drawbacks; reaction times can be slow, the product and starting material have difficulty passing through the cell wall, and each cell must be reprogrammed to produce a new molecule, said Dr. Britton. Debut Bio envisions an alternative route.

In Debut Bios system, reactants are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based systems. The platform technology operates under a continuous manufacturing regime that will provide scale, consistency, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio has currently partnered with two large manufacturers to integrate its platform into their existing pipelines. The seed funding will be used to support these integrations, expand business development, double the science team, and create a pilot production system.

Were humbled to have received both support and validation from world class, science-focused investors, said Brady Beauchamp, COO and Co-Founder of Debut Biotechnology. We plan to build on this validation in the coming months with our initial customers in the pharmaceutical manufacturing industry.

This funding comes following an announcement last year that the company spun out of UC Irvine with the exclusive license of two inventions developed by Dr. Joshua Britton and Professor Greg Weiss.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Wess, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Read more:
Debut Biotechnology Closes $2.6M Seed Round to Bring Continuous Biomanufacturing of High-Value Molecules to Pharma - PR Web

Therapix Biosciences Ltd - ADR (TRPX) is near the bottom in its industry group according to InvestorsObserver. TRPX gets an overall rating of 4. That means it scores higher than 4 percent of stocks. Therapix Biosciences Ltd - ADR gets a 1 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Therapix Biosciences Ltd - ADR (TRPX) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 4 means the stock is more attractive than 4 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Therapix Biosciences Ltd - ADR (TRPX) stock is lower by -6.25% while the S&P 500 is up 0.09% as of 1:52 PM on Friday, Jan 10. TRPX has fallen -$0.06 from the previous closing price of $0.88 on volume of 71,454 shares. Over the past year the S&P 500 is up 26.22% while TRPX has fallen -77.93%. TRPX lost -$2.40 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Therapix Biosciences Ltd - ADR click here.

View post:
Is Therapix Biosciences Ltd - ADR (TRPX) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

The 38th annual JPMorgan Healthcare Conference, which is tipped off as the biggest health care investment symposium, kicks off Monday in San Francisco, California.

From the high and mighty to the smallest of nanocaps, biopharma and health care companies have scheduled presentations at the four-day event. It's a no-brainer that the presentations will move stocks and serve as key catalysts for respective companies.

BofA Securities analyst Geoff Meacham expects investors to be acutely focused on 2020 expectations and the potential to maintain the positive momentum of 2019's year-end rally. The analyst is bracing for a conservative tone from larger-cap names, given the moderate but improving growth expectations that would offer scope for multiple guidance revisions throughout the year.

Meacham expects discussions at the conference to be focused on value creating themes such as expanding indications, new product cycles, especially with oncology, inflammation & immunology and orphan diseases and advancing innovation in gene/cell therapy.

"Combined with the unlikelihood of near-term major structural reform and P/E ratios that now lag improving expectations, we remain positive on the sector and the outlook for multiple expansion, with greater generalist participation," Meacham wrote in a note this week.

Here's what BofA expects from some key presenters in its coverage universe.

See also: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Bristol-Myers Squibb Co (NYSE: BMY)

Bristol-Myers Squibb, which completed the acquisition of Celgene late last year, is likely to give at least partial guidance. Meacham believes 2020 guidance could be an early positive driver of shares.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

The analyst expects Vertex to provide fourth-quarter update on its cystic fibrosis agent Trikafta, with the analyst expecting sales of $223 million, well above the consensus estimate of $64 million.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

BioMarin could delve on the commercial opportunity of valrox and vosoritide following the filing for the former and positive Phase 3 data for the latter.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Regeneron is likely to release fourth-quarter sales of Eylea. Given Eylea's declining growth, Meacham said the focus could shift to Dupixent, which remains a key P&L driver.

Biogen Inc (NASDAQ: BIIB)

BofA expects Biogen to specify the timing of its aducanumab regulatory filing, if it hasn't been already submitted. The company could also announce a settlement with Mylan NV (NASDAQ: MYL) over the Tecfidera intellectual property right.

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Meacham expects Alexion to focus on its portfolio diversification strategy, especially due to pressure from activists and competitors. Updates on ALXN1830 and anti-Factor D ACH-5228 is likely.

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead is likely to update on its global launch plans for filotinib, with the second half of 2020 being the likely timeframe.

Amgen, Inc. (NASDAQ: AMGN)

Meachem expects Amgen to discuss the integration of Otezla into its I&I franchise, update the status of assets in its oncology pipeline and give its expectations for the launch of its biosimilars.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original post:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations - Benzinga

Vir Biotechnology (VIR) registered volume of 79390 shares on Wednesday trading session as compared to an average volume of 206.92K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. Listed Shares of the Vir Biotechnology (VIR) moved up 2.05% to trade at $12.43 in the last trading session ended on 01/08/2020. It has a market capitalization of $1.38B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock EPS is $-1.26 against its recent stock value of $12.43 per share.

First we will be looking for the boiling points and excitability of Vir Biotechnology (VIR) stock, it purposes common trait for traders and value investors.

Volatility Indicators for Vir Biotechnology:

Volatility of the Vir Biotechnology remained at 4.22% over last week and shows 5.62% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 0.69.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -1.15% during the period of last 5 trading days. The stock maintained for the month at -1.51%. The stock noted year to date 2019 performance at -1.15% . The stock is now standing at -24.67% from 52 week-high and is situated at 6.69% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 45.47.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently down -0.87% from its 20 days moving average and trading -5.32% below the 50 days moving average. The stock price has been seen performing along below drift from its 200 days moving average with -6.63%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Link:
What to Consider on Vir Biotechnology (VIR) Stock? - News Welcome

Palatin Technologies, Inc. (PTN) is near the top in its industry group according to InvestorsObserver. PTN gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Palatin Technologies, Inc. gets a 52 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Palatin Technologies, Inc. (PTN) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Palatin Technologies, Inc. (PTN) stock is down -7.31% while the S&P 500 has risen 0.09% as of 1:53 PM on Friday, Jan 10. PTN has fallen -$0.05 from the previous closing price of $0.74 on volume of 1,958,045 shares. Over the past year the S&P 500 is up 26.22% while PTN has fallen -8.00%. PTN earned $0.14 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 4.98.

To screen for more stocks like PTN click here.

Read more:
Is Palatin Technologies, Inc. (PTN) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susans post? Respond in the comments section below.

In all candor, I had no long-term intentions in February 2013 when I started this irregular series tracking biotechnology in countries starting with the letter I. While touching on topical developments for biotech in Iceland, Iran, Ireland, and Italy (Part 3 and Part 11), Israel and India figured prominently due to my direct experience. I first wrote about Israel in February 2013 as the first installment in the series, and have returned to chart ongoing developments (Part 5, Part 8 and Part 12), and India (Part 2, Part 7, Part 10). (Along the way, I also posted a separate 2-part series anticipating changes in policy at the start of the first Modi Administration here and here.)

In retrospect, both Israel and India bear witness to the transformative power of intellectual property (IP) protection for commercial development of biotechnology. So I thought it would be fun to start off the 2020s by taking stock of just how much has changed for innovative life sciences over the last decade, with this additional installment on Israel (and another in the coming weeks on India).

To recap: I first started tracking Israels IP regime in 1994 as a Second Secretary at the Economic Section of the US Embassy. At that time, Teva was Israels largest private employer and had very definite views on Israels implementation of the new WTO Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Suffice it to say, when Teva talked, the Government of Israel listened.Consequently Israel backtracked on early commitments to implement effective marketing exclusivity for pharmaceuticals (TRIPS 39.3 obligations) and also dragged its feet on needed patent law reforms. Throughout my remaining tenure at the State Department, subsequent efforts at PhRMA (Fall 1999 Summer 2005) and beyond, Israel resisted adopting IP reforms needed to promote investment in commercialization of innovative life sciences.

Recognized as the Start-Up Nation for many years, Israel leveraged excellence in basic science for successful commercialization of military, communications and related technologies, and expected similar success in innovative biopharma. Despite longstanding, generous government support for basic research, effective technology transfer, and broader rule of law culture, however, Israel failed to attract meaningful biotech investment.

At the U.S.-Israel Biotechnology Business Roundtable held on the margins of BIO2010 in Chicago, then Chief Scientist Dr. Eli Opper openly expressed frustration at the absence of global biopharma R&D centers and sought advice on how to improve the enabling environment for biopharma. As noted previously, Israel had focused more on direct subsidies and not on needed legal reforms, and participants in the 2010 breakfast meeting repeatedly raised IP as an important barrier to R&D investment. Although it took some time for Israel to commit fully to necessary reforms, Israel ultimately passed IP reforms important for biotechnology in 2014.

Israels implementation of WTO TRIPS data exclusivity and patent reforms provided an important signal to the international innovative industry, precipitating an unprecedented flowering of innovative technologies.

Highlights include:

Whereas Israeli technologies were previously licensed out at early stages due to the inability to fund translational research, Israels innovative life sciences companies are now well represented across the full innovative life cycle, from Seed through Revenue growth.

The bottom line: IATIs Annual Israeli Life Science Industry Report 2019 estimates that approximately 1600 life sciences companies are active in Israel, nearly double the number in existence in 2010. Israels biotech companies are now able to attract both domestic and foreign investment across a range of established and emerging areas of technology, including agrobiotech, digital health, medical cannibis, the microbiome therapeutics, womens health, regenerative medicine, and more.

And in the process Israel has transformed from a poster-child of TRIPS defiance into a real-world demonstration of the critical importance of effective IP for biotechnology commercialization, even in the Start-Up Nation.

What a difference a decade can make.

About the Author:

President of Finston Consulting, LLC since 2005,Susan Kling Finston is a micro-multinational working with innovative companies on biotechnology, trade and development issues, and KOL in commercialization of microbiome technologies as practical tool for human health. In 2006 she founded the Washington Embassy Network (WEN), a forum for informal and collegial information sharing around trade, tech transfer, IP and the environment. She is a contributing blogger at best of the web biotechblog.com. She also has served as a cleared advisor to the Commerce Department and the U.S. Trade Representative (IPR, Tariff/Trade Facilitation).Past Experience: Foreign Service Officer, Department of State, with overseas postings including London, Tel Aviv and Manila (1988 1999); Motions Clerk, Federal Court of Appeals for the Seventh Circuit, Chicago, Illinois (1986 1988). She is admitted to practice before the Illinois Bar, the U.S. Court of Appeals for the Seventh Circuit, and the U.S. Supreme Court. Foreign languages are Hebrew and French.

Continue reading here:
Biotechnology in Countries Starting with "I" - Part 13:... - Biotech Blog

Global Biotechnology Instrumentation market report

TMR boasts its expertise by collecting 1.2 Mn+ data points every year in its data base. Our dedicated crew of experts are in consistent communication with relevant local distributors, and service providers to gather accurate industry-centric insights. We serve our clients day-and-night and offer reports tailored to the clients needs.

Analysts at TMR, influenced by the potential, have published a report on the global Biotechnology Instrumentation market. As per the report, government support, rising consumption of Biotechnology Instrumentation , and enhanced purchasing capacity of consumers are characterizing the Biotechnology Instrumentation market is expected to grow at a CAGR of xx% over the forecast timeframe 2019-2029.

Reports at discounted rate for early birds!!!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=167

competitive landscape is also included in the report, undertaken with the help of a detailed Porters five forces analysis.

Global Biotechnology Instrumentation Market: Trends and Opportunities

The global biotechnology instrumentation market witnessed significant traction in the past few years owing primarily to the vast rise in demand for biotechnology products for the production of personalized medicine. This emerging area of medicine, which aims to serve consumers through medicines produced by keeping in mind each individuals biological makeup and eliminate the negative effects that could result from mass-produced medicines, is expected to be one of the key consumers of biotechnology products in the next few years.

With the vast rise in the prevalence of a variety of chronic diseases across the globe, the demand for personalized medicines is expected to rise at a significant pace in the next few years. This will also act as a significant growth factor for the global market for biotechnology instrumentation as a rapid surge is expected in the demand for human resources capable of serving the heightened demand for biotechnology products.

The vast rise in the usage of 2D and 3D cell cultures in the field of discovery and manufacture of new drug compounds has also emerged as a key factor boosting the growth of the global biotechnology instrumentation market. A significant rise in research activities surrounding gene expression, especially since the inception of the Human Genome Project, has boosted the global demand for microarrays for studying the expression of genotype or gene clusters, propelling the global biotechnology instrumentation market.

Global Biotechnology Instrumentation Market: Geographical Dynamics

North America and Europe are key markets for biotechnology instrumentation owing to the presence of a large number of some of the worlds largest biotechnology and pharmaceutical companies. The regions are also home to some of the leading universities continuously undertaking research in the field of gene expression, thus leading to vast growth opportunities for the biotechnology instrumentation market. In the next few years as well, these regions are expected to remain at the forefront of the global biotechnology instrumentation market, leading to vast development and growth opportunities for companies wanting to venture into this highly lucrative market.

Developing economies across regions such as Latin America and Asia Pacific are also expected to lead to vast growth opportunities for the market owing to the significant rise in research and development activities in the biotech sector. Research and development arms of several multinational pharmaceutical companies in these regions are also expected to drive the market.

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=167

The Biotechnology Instrumentation market research addresses the following queries:

What information does the Biotechnology Instrumentation market report consists of?

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=167

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.co

Read the original post:
Biotechnology Instrumentation Market's Lead to Remain Unchallenged throughout 2016 2024 - Expert Recorder

New Jersey, United States, The recent report added by Verified Market Research gives a detailed account of the drivers and restraints in the Nanoparticles in Biotechnology and Pharmaceuticals Market. The research report, titled [Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report 2020] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Nanoparticles in Biotechnology and Pharmaceuticals market and the current trends that are likely to shape its future. Primary and secondary research methodologies have been used to put together an exhaustive report on the subject. Analysts have offered unbiased outlook on the global Nanoparticles in Biotechnology and Pharmaceuticals market to guide clients toward a well-informed business decision.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=PJN&utm_medium=005

Top 10 Companies in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Nanoparticles in Biotechnology and Pharmaceuticals Market is segmented on the basis of product type, applications, and its end users.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=PJN&utm_medium=005

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=PJN&utm_medium=005

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

See the rest here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Top Companies, Business Opportunities and Growth 2020 to 2027 - Primo Journal

The 65 rating InvestorsObserver gives to Amicus Therapeutics, Inc. (FOLD) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, FOLDs 65 overall rating means the stock scores better than 65 percent of all stocks.

Click Here to get the full Stock Score Report on Amicus Therapeutics, Inc. (FOLD) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Amicus Therapeutics, Inc. (FOLD) stock is higher by 0.43% while the S&P 500 has fallen -0.36% as of 9:57 AM on Tuesday, Jan 7. FOLD is higher by $0.04 from the previous closing price of $9.38 on volume of 169,512 shares. Over the past year the S&P 500 is up 26.86% while FOLD has fallen -14.05%. FOLD lost -$1.57 per share the over the last 12 months.

To screen for more stocks like FOLD click here.

Original post:
Is Amicus Therapeutics, Inc. (FOLD) Stock a Good Buy in Biotechnology - InvestorsObserver

Presenting at the Biotech Showcase, 2020 Tuesday, January 14, 2020 10:30 am PST

PhagoMed's presentation at Biotech Showcase will cover its proprietary engineering platform, its lead assets and an outlook to the plans for 2020 and beyond

VIENNA / ACCESSWIRE / January 8, 2020 / PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings, announced today that its chief executive officer, Alexander Belcredi, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

To view the full release with downloadable visuals and more, click here.

Key Takeaways

About PhagoMed

PhagoMed develops phage-based drug candidates to provide a solution in these settings where antibiotics fail. Phages are natural viruses that infect and kill bacteria. Phages and their proteins (such as lysins) are also highly precise and only target individual bacterial species. PhagoMed has developed a proprietary engineering platform to develop drug-grade phages and lysins. During 2019 the team validated the platform and generated two proprietary drug prototypes in two indications of high medical need: a phage cocktail to treat implant-associated infections and a recombinant endolysin to treat Bacterial Vaginosis and re-stabilize the vaginal microbiome.

Contact:

Alexander BelcrediAlexander.belcredi@phagomed.com+43-676 38 11 082CEO | Business & Finance

SOURCE: Phagomed

View source version on accesswire.com: https://www.accesswire.com/572507/PhagoMed-Biopharma-GmbH-PhagoMed-a-pre-clinical-biotechnology-company-targeting-bacterial-pathogens-announced-today-that-its-Chief-Executive-Officer-Alexander-Belcredi-will-present-at-the-Biotech-Showcase-2020-Conference

Read the rest here:
PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive...

In this Agriculture Biotechnology Market Global Industry Analysis & Forecast to 2030 research report, the central factors driving the advancement of this industry were recorded and the business accessories and end overseers were indulgent. This statistical surveying Agriculture Biotechnology report investigates and inspects the industry and determines a widely inclusive estimate of its development and its details. Another perspective that was efficient is the cost analysis of the prime products driving in the Agriculture Biotechnology Industry remembering the overall revenue of the manufacturers.

The following key Agriculture Biotechnology Market insights and pointers are covered during this report:

Request a demo sample: https://prophecymarketinsights.com/market_insight/Insight/request-sample/2913

The prime manufacturers covered during this report are:

Detail Segmentation:

Global agriculture biotechnology market by type:

Global agriculture biotechnology market by application:

Global agriculture biotechnology market by region:

Download PDF Brochure @ https://prophecymarketinsights.com/market_insight/Insight/request-pdf/2913

The report is an entire guide in providing complete Agriculture Biotechnology processes, cost structures, raw materials, investment feasibility, and investment return analysis. The SWOT analysis, market growth, production, profit, and supply-demand statistics are offered

The historical and future trends, prices, product demand, prospects, and Agriculture Biotechnology marketing channels are stated. The current business and progressions, future methodologies, market entrants are explained. The consumers, distributors, manufacturers, traders, and dealers in Business Intelligence (Bi) Software Market are covered. A comprehensive research methodology, market size estimation, market breakdown, and data triangulation is roofed.

Checkout Complete Details Here: https://prophecymarketinsights.com/market_insight/Global-Agriculture-Biotechnology-Market-By-2913

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Browse Similar Reports:

The rest is here:
Global Agriculture Biotechnology Market Perspective with Study of Leading Players and Revenue to Significant Growth Forecast by 2030 - Primo Journal

Madeleine Dipenaar has already been to the US space agency Nasa in Houston Texas where she met astronauts testing travel to Mars.

South Africa's top matriculant from the class of 2019, Madeleine Dippenaar. Picture: Kayleen Morgan/EWN

JOHANNESBURG - Madeleine Dipenaar from the Northern Cape is the top-performing pupil of 2019.

The young South African woman has already been to the US space agency Nasa in Houston Texas where she met astronauts testing travel to Mars.

Dipenaar is the second of three girls in her home. She said she had been top of her class since grade 8 but she never expected to top the whole country.

I was shocked when I got the call. I thought I could be top 10 provincially but not nationally.

Madeleine was one of two students from South Africa who visited Nasa in 2018 to study a project about human travel to Mars.

Her interest is in biology.

Im going to study molecular biology and biotechnology.

Madeleine said that she had yet to decide what to do with the qualifications she would acquire.

To get your results, visit matric.ewn.co.za

Go here to read the rest:
SAs top matriculant to focus on molecular biology and biotechnology - Eyewitness News

Perthera is a cancer therapeutic intelligence company that leverages Artificial Intelligence (AI) and data-driven therapy recommendations for oncologists to offer precisely tailored treatments to cancer patients based on their genetic factors, molecular profile and much more. The company was founded seven years ago by a team of experts in oncology, biomarkers, bioinformatics, and AI, and has since become a prominent force in bringing precision medicine to oncology. Read on to hear what Gary Gregory, Perthera CEO and President, had to say to DocWire Newsregarding his companys innovative work.

Gary noted that Pertheras primary goal is to harness all the benefits and opportunities of precision medicine in oncology. He added that the patients entire medical and treatment history, as well as their unique, multi-omic molecular profile position, is factored into the Perthera Platform, which is used by the physician to create their customized treatment plan. The patients comprehensive clinical information is run through the companys Therapeutic Intelligence EngineTM, which includes multiple databases, heuristic rules, algorithms and AI, that ultimately delivers a ranked set of therapeutic recommendations that the patients physician can consider. The AI built into the Perthera Platform leverages its computational engine and multiple databases to compile and utilize real-world evidence (RWE) to improve patient outcomes.

We also run each and every patient through our patented, cloud-based, molecular tumor board that allows us to scale a unique and powerful solution, Gary added. This contrasts with most cancer centers where less than 10% of patients typically have the benefit of a molecular tumor board, which has been proven to be highly advantageous from a medical practice perspective.

Another facet of Pertheras mission is to equip pharma, biotech, drug development companies and clinical trial organizations (CROs) with real-world evidence and clinical services that can enable them to expedite drug development, enhance market surveillance of these drugs and accelerate their clinical trials enrollment.

Regarding the advancement of their current technology, Gary noted that the company is always striving to advance Pertheras proprietary algorithms, use of real-world evidence, deployment of AI, and integration of new molecular technologies to continually improve their precision oncology solution.

Were also involved in a number of exciting projects with industry, whether its with pharma companies, CROs or advocacy groups, he added. We partner with them to bring forward their initiatives, the developmental work theyre doing on new therapeutic agents, theyre detailing the clinical efficacy of precision medicine, and even the clinical utility of Pertheras Platform, which has been proven to provide a significant improvement in both overall and progression-free survival.

Pertheras main offering is a Precision Medicine Program for Hospitals and Physicians, which allows healthcare providers to harness and capitalize on the benefits of Pertheras precision oncology platform. This program starts with the physician ordering the Perthera Platform and clinical report. Perthera completely de-burdens the clinical staff by orchestrating all molecular profiling tests, and running the comprehensive clinical information through its Therapeutic Intelligence EngineTM, and then an expert Molecular Tumor Board, consisting of a variety of medical experts, to ultimately produce the ranked therapeutic options.

Next, Perthera delivers a personalized report that is precisely matched to each patient, and contains specific, ranked therapeutic recommendations that are supported by medical, clinical, and scientific evidence, to promote expanded progression-free survival and overall survival outcomes.

The final step in this process involves Pertheras following the patient and capturing comprehensive RWE data regarding the patients treatment and outcomes.

And the physicians and hospitals can use this data for research purposes, whether its for publications, for accelerating their own clinical trials, or simply to advance the care of their patients, Gary explained. The data we collect is made available for their use. We provide it back to them via a dedicated portal so that they can take full advantage of the understanding, analysis and utilization of their specific data, to advance their practice of medicine and care of their patients.

Its also important to note that Perthera now customarily delivers their Platform at low to no charge to hospitals, physicians and patients. This approach has been transformative in allowing many healthcare organizations to capitalize on the Perthera Platform and all it offers to providers and patients.

The computational engine, or Therapeutic Intelligence EngineTM, is at the center of what Perthera offers healthcare providers and patients. This is founded upon their proprietary, comprehensive computational system that Perthera has been building over the course of six plus years.

It features 10 distinct databases and over 50,000 heuristic rules, algorithms and AI, he explained. Every patients data is analyzed by Pertheras Therapeutic Intelligence EngineTM. We provide an initial set of computationally ranked therapies, and then the patients clinical data and information is analyzed and polished by our expert, cloud-based, Molecular Tumor Board which provides the highly unique human in the loop component of our Platform. The byproduct of these elements is the Perthera Report, which has these precisely ranked therapeutic recommendations (including on label, off label and clinical trial options) for the physician to evaluate, choose from and direct their patients medical therapies. As we collect RWE outcomes and treatment selections, we incorporate that data back into our Therapeutic Intelligence Engine, which gains experience over time, to further improve our service and the resulting clinical outcomes.

As previously mentioned, research has shown that if the top-ranked therapies that Perthera suggests are chosen, survival rates are significantly more likely to be improved.

Beginning his work with Perthera in the past year, Gary noted that one of the first things he saw in the company was their proven approach to precision oncology, that was backed by reputable clinical research publications.

Our Platform and service is clinically proven in the sense that its been delivered to over 250 cancer centers and utilized by well over 10% of practicing oncologists across the U.S., he explained. Its also proven through peer-reviewed publications that detail when physicians use the Perthera Platform, they do a better job of harnessing the power of precision medicine and they improve their patient outcomes, both from an overall and progression-free survival.

Its a really exciting clinical arena and marketplace. The care of cancer patients is being transformed before our eyes. As importantly, its an exciting time for Perthera, because we believe were the only company that offers this end to end Platform, that has been proven to advance the care of patients, and also to deliver better clinical outcomes, he concluded. The comprehensive, end-to-end nature of what we do makes Perthera highly unique, and allows us to deliver exceptional value to patients, physicians, hospitals and biopharma companies.

Link:
How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology - DocWire News

Editors note: January is Pancreatic Cancer Clinical Trials Awareness Month. Throughout the month, we will feature a Shedding Light on Clinical Trials series that provides key information about clinical trials and how they can benefit pancreatic cancer patients. Todays article gives an overview of the current clinical trial landscape.

There are approximately 170 pancreatic cancer clinical trials currently enrolling patients across the United States. These clinical trials are open at cancer centers, hospitals and community medical practices throughout the country.

The Pancreatic Cancer Action Network (PanCAN) maintains the most comprehensive and up-to-date database of pancreatic cancer clinical trials available in the United States.

Clinical trials are designed to determine whether an experimental treatment or combination is effective, safe and an improvement over the current standard of care options. Participants must meet specific eligibility criteria, which can include their type of pancreatic cancer, the stage of disease, treatment history and other health and wellbeing requirements.

While most clinical trials strive to answer similar questions, the way the trial is designed can vary.

In recent years, theres been an increase in biomarker-driven clinical trials for pancreatic cancer patients.

Biomarkers are biological clues that can be measured from a patients blood, urine, tumor tissue or other specimens. The presence or amount of a biomarker may vary between someone whos healthy and someone with a disease like pancreatic cancer.

Moreover, through a precision medicine approach, biomarkers can provide information about whether a patient is likely to respond to a certain type of treatment.

Some clinical trials are designed to only enroll patients with expression of certain biomarkers, while other trials strive to find biomarkers that could predict a patients response to their experimental treatment.

PanCAN recommends all patients with pancreatic cancer undergo testing to analyze their tumors molecular profile (through testing a sample of tumor tissue) and to determine if they have germline (genetic) alterations that they were born with (through analysis of their blood or saliva).

Both tests are available through PanCANs Know Your Tumor precision medicine service. Patient Central can provide information about Know Your Tumor and other ways to access these tests, as well as provide a list of biomarker-driven clinical trials that may be relevant to the patient.

Another type of trial, adaptive platform trials, allow investigators to ask multiple questions at the same time, rather than testing only one experimental drug against the standard of care.

Adaptive platform trials are designed to learn and evolve over time, with the expectation that additional experimental treatments will be added. If an experimental treatment arm isnt performing well within the trial, it can be discontinued at any time.

Todays pancreatic cancer clinical trials are being designed based on rigorous scientific and clinical evidence and to quickly and efficiently evaluate experimental treatment options to benefit patients.

Pancreatic cancer patients who participate in clinical research have better outcomes. Every treatment available today was approved through a clinical trial. PanCAN strongly recommends clinical trials at diagnosis and during every treatment decision.

View post:
Evaluating the Pancreatic Cancer Clinical Trial Landscape - Pancreatic Cancer News & Stories

Exercising and eating better as part of our new year health kicks are great, but we should also think more deeply about the role the environment plays on our health. As a professor of environmental medicine, I believe this is an exciting new area of study that will play a big part in the future of personalized medicine.

Consider this, every day we are bombarded with messages: genes that cause cancer, supplements that prevent Alzheimers disease, diets that prevent asthma, chemicals that make us gain weight. But while headlines frequently proclaim game changing new findings, over the last 20 years in the US and Europe our health status as a population has seriously deteriorated. Rates of obesity, diabetes, heart disease, cancer and learning disorders continue to rise. Genetic variation may be part of the puzzle that explains why we get sick, but clearly there are missing pieces.

After all, 20 years of increasing obesity and diabetes represents only a single generation. If our genes didnt change in the last 20 years, then our environment must have.

Genes never work in isolation. Instead, they determine how we react to our diet, social surroundings, physical environment, infections and chemical exposures. Environment is the missing piece of the puzzle.

The old 20th-century concept of nature v nurture needs to be redefined, as genetics and environment do not compete, they work hand in hand, sometimes to our benefit and sometimes to our detriment. The correct formula is really nature times nurture. Right now the nurture part of that equation is largely unknown, but that may soon change.

Recently, a new concept has arisen, the science of the exposome: the measurement of all the health-relevant environmental factors across the lifetime.

The exposome is to our environment what genomics is to our genetics. Most of what we know about environment and health is still a black box consisting of yet to be discovered risk factors we too often attribute to bad luck ie because we dont measure the environmental cause, the problem appears random.

But most of what we now understand about genetics was also a black box in the 20th century.

Physicians see the role of environment daily even if it is not clear to them that environment is the cause. For example, a child with autism develops more frequent combative oppositional behaviors and emotional outbursts. An adult with diabetes cant seem to control her blood sugar despite higher doses of insulin. A newborn is born with blue skin but a normal heart.

For each of these cases, sequencing the genome would not have identified the cause. The autistic child had lead poisoning because of pica brought on by autism, the diabetic adult used perfumes high in phthalates, chemicals that affect metabolism and the newborn baby drank formula mixed with well water contaminated by fertilizer runoff that reacted with his hemoglobin.

In each case, genomics would not have given us the correct answer, but if we had the tools to measure the exposome, we would have made the correct diagnosis. Just as importantly, because the underlying causes were environmental, we can treat the problem with interventions.

Furthermore, in most diseases, environment and genetics work in combination. Its very rare to have a genetic variant that causes Alzheimers disease, but it is fairly common to have a genetic variant that makes us susceptible to environments that can cause Alzheimers. The different between those with the genetic variant who get sick and those who dont is their different environments.

Imagine a visit to your physician in which you begin by handing over your smartwatch to have its data downloaded, followed by a blood draw to measure your chemical environment and nutritional status, then you update your lifetime home address and occupational history into a secure computer that houses your genomic data. This then computes your personalized risk score for heart disease, diabetes and other diseases. Or, if you already have one of these diseases, computes the ideal treatment regimen based on this big data. This is how we will be able to personalize medicine.

We are not there yet, but the technology to measure the exposome is far more advanced than the general public, and even many researchers, realize. There are now lab tests that can demonstrate the presence of thousands of chemicals in our bodies and satellites that record our daily weather, air pollution, light exposure and built environment. Public records have data on water quality, age of housing, local crime statistics, outdoor noise levels and even where disease clusters are occurring. Cellphones are ubiquitous and can link our daily behavior and movement patterns with the quality of the local air and water while simultaneously measuring our heart rate, physical activity and sleep quality.

Computational science has advanced to a point where storage of terabytes of data is routine and computer clusters are found in every major university and methods to bring these databases together are no longer science fiction. Artificial intelligence and other big data approaches to genomics also provide a roadmap for analyzing exposomic data.

Understanding how environment affects your health will empower people to make the changes in their lifestyle that will matter most. To understand what food to buy, which fragrances to avoid, where and when to exercise, etc. All the pieces to solve this puzzle are beginning to come together. What is needed is the grand vision to invest in and integrate exposomic science into public health and clinical medicine. This is the final piece of the puzzle. Once we understand our exposome and integrate it with our genome, we will finally understand why and how chronic diseases have become so common and how we can start to reverse their trends in society.

Dr Robert Wright is a pediatrician, medical toxicologist, environmental epidemiologist and director of the Institute for Exposomic Research at the Icahn School of Medicine at Mount Sinai

Continue reading here:
New year health kicks are great but your environment is also vital - The Guardian